Breaking news on cervical cancer and HPV
Health Discovery Corporation And DCL Medical Laboratories To Develop A Computer Assisted Diagnostic Test For Cervical Cancer published
Thu, 08 May 2008 02:00:00 PDT
Health Discovery Corporation (OTCBB: HDVY), a leader in support vector machine (SVM) based molecular diagnostics development, and DCL Medical Laboratories LLC, Indianapolis, IN, a full-service clinical reference laboratory focused on women's health, today announced the signing of a Letter of Intent for the companies to jointly develop an SVM-based computer assisted diagnostic (CAD) test for the analysis of cervical cells.
Kansas Breast And Cervical Cancer Screening Program For Low-Income, Uninsured Women Runs Out Of Funding published
Wed, 07 May 2008 07:00:00 PDT
The Kansas Early Detection Works program, which provides uninsured low-income women in the state with breast and cervical cancer screenings at no cost, has depleted its operating funds and will delay almost all cancer screenings until July 1, the Wichita Eagle reports.
New Zealand Prime Minister Announces Funding For New HPV Vaccine Program published
Tue, 06 May 2008 09:00:00 PDT
New Zealand Prime Minister Helen Clark on Friday announced a new program that will provide about $128 million over five years to vaccinate girls ages 12 to 18 against cervical cancer, the New Zealand Herald reports. As of Sept.
Mothers More Willing To Have Older Daughters Vaccinated Against HPV, Study Finds published
Tue, 06 May 2008 07:00:00 PDT
Although CDC recommends that girls receive the human papillomavirus vaccine at age 11 or 12 to protect against cervical cancer before the onset of sexual activity, mothers of girls under age 13 are less willing to have their daughters vaccinated than mothers of older girls, a new study has found, the
Are U.S. Mothers Ready To Vaccinate Their Daughters Against HPV? published
Tue, 06 May 2008 02:00:00 PDT
Certain strains of human papillomavirus (HPV) are sexually transmitted and can cause cervical cancer and genital warts. In 2006, the U.S. Food and Drug Administration approved Gardasil, a prophylactic HPV vaccine marketed by Merck. It is recommended for girls and women 9 to 26 years old, but in almost all states, it is not mandated.
Explaining Cervical Cancer Prevention published
Tue, 06 May 2008 02:00:00 PDT
Cervical cancer prevention relies on two different age-specific technologies, and consumers should not be misled about the role of human papillomavirus (HPV) vaccines, according to an article in the latest edition of The Medical Journal of Australia.
Michigan Legislature Passes Bill To Make HPV Information Available To Girls, Families published
Mon, 05 May 2008 08:00:00 PDT
The Michigan Senate earlier this week passed a House-approved bill (HB 5322) that directs schools that provide information on immunization to families and students in at least grades six, nine, and 12 to include information about human papillomavirus and the HPV vaccine, the AP/MLive.
Mothers Less Likely To Pursue HPV Vaccination For Youngest Daughters published
Thu, 01 May 2008 00:00:00 PDT
Because the first national study of its kind has found that U.S. mothers report they are less likely to vaccinate daughters under age 13 against human papillomavirus virus (HPV), even though the vaccine is recommended for girls at age 11 and 12, it's incumbent upon the healthcare community to work to improve moms' acceptance of the vaccination for younger daughters, say researchers at Cincinnati Children's Hospital Medical Center who conducted the study.
Cervical Cancer Screening Program Review Shows Effectiveness And Room For Improvement published
Wed, 30 Apr 2008 02:00:00 PDT
Women who do not undergo regular cervical cancer screening tests are more likely to be diagnosed with the disease than those who do, according to an audit of the Swedish national cervical cancer screening program published online April 29 in the Journal of the National Cancer Institute. Participation in screening reduces the risk for all types of cervical cancers in all ages.
Third Wave Completes FDA Submissions For Its Two HPV Products published
Wed, 30 Apr 2008 01:00:00 PDT
Third Wave Technologies Inc. (NASDAQ: TWTI) announced that the company has submitted the pre-market approval (PMA) applications for its two human papillomavirus, or HPV, testing products to the U.S. Food and Drug Administration. "The submission of Third Wave's two HPV PMA applications marks the completion of a monumental undertaking by the entire Third Wave team," said Kevin T. Conroy, president and chief executive of Third Wave.
Clinical Trial Results Show Proof-of-Concept For Use Of Coriolus Versicolor As Immunonutrition In HPV Patients With Cervical Lesions (LSIL) published
Tue, 29 Apr 2008 01:00:00 PDT
The results of a year long clinical trial examining the effects of mushroom supplementation in patients with Human Papillomavirus (HPV) have recently been presented at congress. Dr. Jose Silva Couto and Dr. Daniel Pereira da Silva of the Cervical Pathology Unit of the Portuguese Institute of Oncology in Coimbra, Portugal presented their findings at the 20th European Congress of Obstetrics and Gynaecology, in Lisbon Portugal.
HPV Vaccine Uptake published
Mon, 28 Apr 2008 05:00:00 PDT
A third of parents could refuse to allow their teenage daughters to receive a new cervical cancer vaccination, The Daily Telegraph reports. Results from a study show that a "significant proportion of parents will not give permission for their child to receive the injection", the newspaper says. It works by stopping the spread of the human papilloma virus (HPV), a primary cause of cervical cancer.
Nventa Completes Safety Evaluation On Final Cohort In HspE7 Phase 1 Cervical Dysplasia Trial published
Fri, 25 Apr 2008 00:00:00 PDT
Nventa Biopharmaceuticals Corporation (TSX: NVN) announced the completion of the safety and tolerability assessment of the fourth and final cohort of patients in its Phase 1 clinical trial of HspE7, its lead therapeutic candidate, in women with cervical intraepithelial neoplasia (CIN). Findings from the fourth cohort safety review demonstrated that HspE7 was safe and well tolerated with no serious adverse events being reported.
Actions Taken On Women's Health-Related Legislation In Iowa, Kansas, Missouri published
Thu, 24 Apr 2008 07:00:00 PDT
The following highlights recent state news about women's health-related legislation. Iowa: Gov. Chet Culver (D) on Friday signed a bill (HF 2145) into law that will require all state-regulated health insurance plans that cover vaccinations to cover human papillomavirus vaccines, the
The Importance Of 'Mind-Body' Connection For Surviving Cancer published
Wed, 23 Apr 2008 04:00:00 PDT
A unique telephone-counseling intervention not only improved the quality of life for cervical cancer survivors but also altered associated stress-related effects on their immune systems, a UC Irvine study has found.Along with reporting psychological and social benefits, the women in the study were found to have improved anti-tumor immune responses. The findings point to the importance of a "mind-body" connection for surviving cancer with a higher quality of life.
VivaGel Inhibits Clinically Relevant Strains Of Human Papillomavirus (HPV) In Laboratory Tests published
Mon, 21 Apr 2008 03:00:00 PDT
Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) announced that recent studies have shown that SPL7013, the active ingredient in its topical microbicide VivaGel(R), inhibits clinically-relevant strains of the human papillomavirus (HPV) in laboratory tests. Starpharma CEO, Dr Jackie Fairley said: "These are exciting results which have positive implications for VivaGel(R), and which merit further investigation.
Insert Therapeutics To Initiate A Multinational Phase II Clinical Trial Of Lead Drug Candidate IT-101 In Ovarian Cancer published
Mon, 21 Apr 2008 01:00:00 PDT
Insert Therapeutics, Inc., a majority owned subsidiary of Arrowhead Research Corporation (ARWR), announced that it has filed with the U.S. Food and Drug Administration to initiate a Phase II clinical trial evaluating the safety and efficacy of its drug candidate IT-101 in patients with ovarian cancer. In women who receive a 2nd course of chemotherapy, nearly 75% will achieve some degree of disease stabilization.
The Fallopian Tube Epithelium As The Field Of Origin For Ovarian Serous Carcinoma published
Thu, 17 Apr 2008 03:00:00 PDT
Researchers report the fallopian tube fimbria rather than ovarian surface cells may be the site of origin for over 50 percent of sporadic and hereditary serous carcinoma, the most aggressive form of ovarian cancer. The new knowledge may enable earlier detection, better treatment and potential prevention of the most lethal gynecologic malignancy in Western countries.
The First Use Of A Live Listeria Cancer Vaccine In Humans published
Wed, 16 Apr 2008 03:00:00 PDT
Phase I/II trial results have shown that the live Listeria cancer vaccine, Lovaxin C, is safe for humans. In addition, three women in the cervical cancer trial had approximately 20 percent tumor reductions, researchers report. "We are using Listeria to deliver tumor-specific antigens to the immune system in a manner that results in maximal immune and tumor-clearing response," said John Rothman, Ph.D.
Cervical Screening Awareness Week 21 - 27 April 2008, UK published
Wed, 16 Apr 2008 03:00:00 PDT
Camden Primary Care Trust, supported by Jo's Trust, a cervical cancer charity, is spearheading a national Cervical Screening Awareness Week from the 21st to 27th April 2008. The campaign is being launched, to raise awareness of cervical cancer and to ensure that women aged between 25 and 64 years know how important it is to attend their cervical screening appointment when they are invited.
Quebec To Offer Schoolgirls Free HPV Vaccines published
Mon, 14 Apr 2008 12:00:00 PDT
Girls from Quebec, Canada, in grades four and nine will be able to receive the HPV (human papilloma virus) vaccine if their parents request it. This will bring Quebec in line with other Canadian provinces. Authorities say this move will cost Quebec approximately CA$50 million this year. The Quebec government said it hopes all young women will receive the HPV vaccine eventually.
Unnecessary Treatment Of Some Cervical Cancer Patients Can Be Prevented By MRI And PET/CT published
Mon, 14 Apr 2008 03:00:00 PDT
MRI and PET/CT can help spare patients with clinically operable cervical cancer from unnecessary high-morbidity treatment, however, pretreatment imaging does not lead to increased survival of these patients, a new study shows."We developed a decision-analytic model to determine the value of pretreatment imaging in the patients with stage 1B cervical cancer," said Pari Pandharipande, MD, MPH, of Massachusetts General Hospital in Boston, and lead author of the study.
First Of Its Kind: HPV Resource Created For Adolescents And Parents published
Tue, 08 Apr 2008 02:00:00 PDT
Educating preteens and teenagers about their sexual health is no easy task, even for many health care professionals. The Association of Women' s Health, Obstetric and Neonatal Nurses (AWHONN) hopes to change that, at least when it comes to talking about the human papillomavirus (HPV), with its newly released resource, " HPV Counseling: A Clinician Resource.
Cervical Cancer Screening published
Fri, 04 Apr 2008 00:00:00 PDT
The Pap test has been the standard screening tool for cervical cancer for years -- and it still is. The test checks a sample of cervical cells under a microscope for abnormalities that may lead to cancer.Lessons learned in the past several years are leading to changes in recommended screening frequency, and a new test is under study, according to the April issue of Mayo Clinic Women's HealthSource.
News From The Annals Of Internal Medicine April 1, 2008 published
Tue, 01 Apr 2008 04:00:00 PDT
1. Perils of Testing: What Happens When Tests for Cervical Cancer are Normal but HPV Testing Is Abnormal?When nearly 10,000 women were screened with Pap tests for cervical cancer and with DNA tests for high-risk human papillomavirus (HPV), 23 percent were found to be infected with high-risk HPV regardless of status on the Pap test (Article, p. 493.)HPV is considered the major cause of cervical cancer.
)
|
|
